Oddo BHF Asset Management Sas Purchases Shares of 18,224 Labcorp Holdings Inc. $LH

Oddo BHF Asset Management Sas purchased a new stake in Labcorp Holdings Inc. (NYSE:LH) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 18,224 shares of the medical research company’s stock, valued at approximately $4,572,000.

Several other large investors have also recently bought and sold shares of LH. Thurston Springer Miller Herd & Titak Inc. bought a new position in Labcorp in the 4th quarter valued at about $26,000. Hilton Head Capital Partners LLC bought a new position in shares of Labcorp during the fourth quarter worth approximately $27,000. JPL Wealth Management LLC bought a new position in shares of Labcorp during the third quarter worth approximately $28,000. Eagle Bay Advisors LLC bought a new position in shares of Labcorp during the fourth quarter worth approximately $29,000. Finally, Beacon Financial Strategies CORP bought a new position in shares of Labcorp during the fourth quarter worth approximately $33,000. 95.94% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

LH has been the topic of several recent research reports. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Labcorp in a report on Friday, May 8th. Wall Street Zen cut shares of Labcorp from a “buy” rating to a “hold” rating in a report on Saturday. Robert W. Baird set a $334.00 target price on shares of Labcorp in a report on Friday, May 1st. Morgan Stanley reaffirmed an “overweight” rating on shares of Labcorp in a report on Tuesday, February 17th. Finally, Piper Sandler raised their target price on shares of Labcorp from $270.00 to $300.00 and gave the stock a “neutral” rating in a report on Tuesday, February 24th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Labcorp has a consensus rating of “Moderate Buy” and an average target price of $308.00.

Insider Buying and Selling

In other Labcorp news, EVP Kathryn W. Kyle sold 762 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $263.89, for a total value of $201,084.18. Following the sale, the executive vice president owned 3,813 shares in the company, valued at $1,006,212.57. This trade represents a 16.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Adam H. Schechter sold 5,903 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $254.50, for a total transaction of $1,502,313.50. Following the completion of the sale, the chief executive officer owned 107,234 shares in the company, valued at $27,291,053. This represents a 5.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.84% of the company’s stock.

Labcorp Stock Performance

NYSE LH opened at $264.61 on Tuesday. The company has a current ratio of 1.73, a quick ratio of 1.54 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $21.70 billion, a price-to-earnings ratio of 23.44, a P/E/G ratio of 1.86 and a beta of 0.90. The firm’s 50 day simple moving average is $262.46 and its 200 day simple moving average is $265.74. Labcorp Holdings Inc. has a 1 year low of $241.81 and a 1 year high of $293.72.

Labcorp (NYSE:LH) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.09 by $0.16. The business had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.51 billion. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the business posted $3.84 EPS. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. As a group, research analysts expect that Labcorp Holdings Inc. will post 18 earnings per share for the current fiscal year.

Labcorp Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, June 11th. Investors of record on Friday, May 29th were given a dividend of $0.72 per share. The ex-dividend date was Friday, May 29th. This represents a $2.88 annualized dividend and a dividend yield of 1.1%. Labcorp’s dividend payout ratio (DPR) is currently 25.51%.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.